Design and rationale of the QUAZAR Lower-Risk MDS (AZA-MDS-003) trial: a randomized phase 3 study of CC-486 (oral azacitidine) plus best supportive care vs placebo plus best supportive care in patients with IPSS lower-risk myelodysplastic syndromes and poor prognosis due to red blood cell transfusion-dependent anemia and thrombocytopenia by Garcia Manero, Guillermo et al.
Garcia-Manero et al. BMC Hematology  (2016) 16:12 
DOI 10.1186/s12878-016-0049-5STUDY PROTOCOL Open AccessDesign and rationale of the QUAZAR
Lower-Risk MDS (AZA-MDS-003) trial:
a randomized phase 3 study of CC-486
(oral azacitidine) plus best supportive care
vs placebo plus best supportive care in
patients with IPSS lower-risk
myelodysplastic syndromes and poor
prognosis due to red blood cell
transfusion–dependent anemia and
thrombocytopenia
Guillermo Garcia-Manero1*, Antonio Almeida2, Aristoteles Giagounidis3, Uwe Platzbecker4, Regina Garcia5,
Maria Teresa Voso6, Stephen R. Larsen7, David Valcarcel8, Lewis R. Silverman9, Barry Skikne10 and Valeria Santini11Abstract
Background: CC-486 is an oral formulation of the epigenetic modifier azacitidine. In an expanded phase 1 trial, CC-486
demonstrated clinical and biological activity in patients with International Prognostic Scoring System (IPSS) lower-risk
(low- and intermediate-1–risk) myelodysplastic syndromes (MDS) with poor prognostic features including anemia
and/or thrombocytopenia who may have required red blood cell or platelet transfusions. The overall response rate
was 40 %, including hematologic improvement in 28 % of patients and RBC transfusion independence sustained for
56 days in 47 % of patients with baseline transfusion dependence. Based on the results of this study, the randomized,
placebo-controlled phase 3 QUAZAR Lower-Risk MDS trial (AZA-MDS-003) was initiated. The design and rationale for
this trial comparing CC-486 with placebo for the treatment of patients with IPSS lower-risk MDS with poor prognostic
features are described.
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Methods: Patients must have IPSS lower-risk MDS with red blood cell (RBC) transfusion–dependent anemia and
thrombocytopenia. Eligible patients are randomized 1:1 to receive 300 mg of CC-486 or placebo once daily for
the first 21 days of 28-day treatment cycles. Disease status assessments occur at the end of cycle 6 and patients
may continue to receive treatment unless there is evidence of progressive disease, lack of efficacy, or
unacceptable toxicity. The primary endpoint is RBC transfusion independence for ≥ 84 days, assessed according
to International Working Group 2006 criteria. Secondary endpoints include overall survival, hematologic response
including platelet response and erythroid response, RBC transfusion independence for ≥ 56 days, duration of RBC
transfusion independence, time to RBC transfusion independence, rate of acute myeloid leukemia (AML)
progression, time to AML progression, clinically significant bleeding events, safety, health-related quality of life,
and healthcare resource utilization.
Conclusions: This study will provide data on the efficacy and safety of CC-486 in the treatment of IPSS lower-risk
MDS with poor prognosis due to the presence of both RBC transfusion–dependent anemia and
thrombocytopenia. Positive results of the AZA-MDS-003 study may expand treatment options for patients with
IPSS lower-risk MDS.
Trial registration: ClinicalTrials.gov NCT01566695, registered March 27, 2012.
Keywords: Myelodysplastic syndromes, MDS, IPSS lower risk, CC-486, Azacitidine, Red blood cell transfusion
dependence, Anemia, ThrombocytopeniaBackground
Myelodysplastic syndromes (MDS) are a heterogeneous
group of clonal myeloid malignancies characterized by in-
effective hematopoiesis, peripheral cytopenias, recurring
cytogenetic and molecular abnormalities, and risk of pro-
gression to acute myeloid leukemia (AML) [1–3]. More
than 10,000 new cases in the United States and 8000 in
Europe are estimated to occur each year [4, 5]; however,
because of its heterogeneity, MDS is challenging to diag-
nose and classify [6]. MDS is primarily a disease of older
age. People aged ≥ 65 years have an annual incidence of
MDS of 75 per 100,000 persons, whereas the incidence is
estimated at only 3.3 per 100,000 persons in the general
population [7]. Due to the heterogeneity of outcomes as-
sociated with this disease, patients are generally stratified
by risk to aid treatment decision making [8]. The Inter-
national Prognostic Scoring System (IPSS) is a standard
tool used for risk assessment of adult patients with de
novo untreated MDS [9]. The IPSS stratifies patients into
4 risk groups: low, intermediate (Int)-1, Int-2, and high
risk, based on cytogenetics, percentage of bone marrow
blasts, and number of cytopenias. Patients with IPSS
lower-risk (low and Int-1) MDS account for approximately
two-thirds of patients and are generally viewed as having a
favorable prognosis. However, a subset of patients in the
IPSS lower-risk group have additional poor prognostic fac-
tors that limit survival, and these patients may benefit
from early therapeutic intervention [10, 11]. More re-
cently, the IPSS-R has been developed to further refine
the IPSS [12].
Anemia and thrombocytopenia are among the most
common characteristics in patients with lower-riskMDS, and their severity may impact prognosis [9, 10].
A study of 856 patients with IPSS lower-risk MDS
found that baseline factors including thrombocytopenia,
anemia at hemoglobin levels requiring red blood cell
(RBC) transfusion, older age, higher percentage of bone
marrow blasts, and poor-risk cytogenetics to be associ-
ated with worse survival [10]. Patients with severe
thrombocytopenia had a median overall survival (OS)
of 15.4 months [10], similar to that of patients with
IPSS Int-2–risk disease [9]. In addition, severe anemia
can lead to RBC transfusion dependence, which is asso-
ciated with decreased quality of life (QOL) and in-
creased morbidity and mortality [11, 13–16]. Currently,
no approved therapies prolong survival in patients with
lower-risk MDS who have both transfusion-dependent
anemia and thrombocytopenia. Standard therapy for
patients with lower-risk MDS with anemia remains
supportive treatment with erythropoiesis-stimulating
agents and RBC transfusions [17]. Erythropoiesis-
stimulating agents may be beneficial for some RBC
transfusion–dependent patients but have no effect on
thrombocytopenia. Thrombopoietin-receptor agonists are
under investigation for the treatment of thrombocytopenia
in MDS; although early clinical trial results are promising,
more data are needed before these agents can be recom-
mended for routine use [18, 19]. Intravenous or subcutane-
ous azacitidine and intravenous decitabine are approved for
treatment of lower-risk MDS in a limited number of coun-
tries and are recommended for the treatment of patients
with thrombocytopenia [17]; however, few data exist re-
garding their use in patients with lower-risk MDS who have
both transfusion-dependent anemia and thrombocytopenia
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ment options to improve outcomes for patients with lower-
risk MDS who have poor prognosis due to the presence of
multiple severe cytopenias.
Results from an alternative dosing schedule study of
subcutaneous azacitidine treatment in patients with MDS,
many of whom were “lower risk” according French-
American-British classification, suggest that patients with
multiple cytopenias may benefit from lower doses of
azacitidine over a prolonged period of time [21]. Although
patient numbers were small, in patients with RBC transfu-
sion–dependent anemia, baseline thrombocytopenia did
not negatively impact rates of RBC transfusion independ-
ence with a lower and more prolonged dosing schedule of
azacitidine. Baseline thrombocytopenia was associated
with lower rates of RBC transfusion independence in pa-
tients who received shorter dosing schedules of a higher
dose of azacitidine.
It is hypothesized and preclinical data suggest that
exposure to azacitidine over a prolonged period of time
at lower doses may result in enhanced DNA hypome-
thylation [22, 23]. CC-486 is an oral formulation of the
epigenetic modifier azacitidine. Oral administration al-
lows delivery of drug over a longer schedule than can
be practically achieved with an injectable agent. There-
fore, extended dosing with CC-486 will eliminate the
requirement of injections and improve the convenience
of prolonged treatment compared with an injectable
formulation. Also, extended dosing with CC-486 may
prolong therapeutic effects compared with shorter dos-
ing regimens.
A recent phase 1 trial demonstrated that CC-486 is
biologically and clinically active in patients with
hematologic malignancies, including MDS, chronic
myelomonocytic leukemia, and AML [24–26]. Part 1 of
this trial was a dose-escalation study of CC-486 admin-
istered once daily for 7 days in 28-day cycles. Azaciti-
dine was administered subcutaneously (75 mg/m2/
day × 7 days) in cycle 1 and then orally with CC-486
(120–600 mg/day × 7 days of every 28-day cycle) from
cycle 2 forward [24]. The maximum tolerated dose of
CC-486 was 480 mg for 7 days of 28-day dosing.
Hematologic responses were observed in patients with
MDS or chronic myelomonocytic leukemia. CC-486
also induced significant hypomethylation of gene loci in
treated patients during cycle 2 vs baseline.
Part 2 of this trial examined the use of CC-486 in ex-
tended 14- or 21-day dosing schedules in 28-day treatment
cycles. Part 2 was later amended to include an expanded
cohort of 53 patients with IPSS lower-risk MDS with poor
prognostic features: anemia or thrombocytopenia with or
without RBC or platelet transfusions [25]. Treatment with
CC-486 at 300 mg once daily for 14 or 21 days resulted in
an overall response rate of 40 %, including hematologicimprovement in 28 % of patients. Additionally, RBC trans-
fusion independence was sustained for ≥ 56 days in 47 % of
patients with baseline RBC transfusion dependence. CC-
486 was relatively well tolerated, and pharmacokinetic
studies showed no evidence of azacitidine accumulation.
Most common grade 3/4 hematologic adverse events in
the 14- and 21-day dosing schedules included neutropenia
(7.7 and 18.5 %, respectively), anemia (11.5 and 7.4 %),
thrombocytopenia (11.5 and 3.7 %), and febrile neutropenia
(3.8 and 11.1 %). Most common grade 3/4 nonhematologic
adverse events in the 14- and 21-day dosing schedules in-
cluded pneumonia (15.4 and 3.7 %, respectively), diarrhea
(7.7 and 11.1 %), vomiting (7.7 and 7.4 %), and cellulitis
(7.7 and 18.5 %) [25]. This is consistent with the known
safety profile of azacitidine for injection in patients with
MDS, aside from injection-site reactions [27]. Further stud-
ies showed that extended dosing of CC-486 administered
at 300 mg once daily for 14 or 21 of 28 days provide sus-
tained DNA hypomethylation through treatment cycle end
[26], especially the 21-day dosing schedule, compared with
7-day dosing schedules.
Based on results of the phase 1 trial, the current ran-
domized, placebo-controlled phase 3 trial was initiated
to investigate the efficacy and safety of CC-486 for the
treatment of patients with IPSS lower-risk MDS with
poor prognostic features. Eligibility criteria include RBC
transfusion–dependent anemia and thrombocytopenia.
This is a subgroup of lower-risk MDS with poor progno-
sis and no effective treatment options exist apart from
transplantation. The design of the QUAZAR Lower-Risk
MDS study, also known as AZA-MDS-003, is described
in the next section. It will hopefully provide important
clinical data to expand treatment options for patients
with IPSS lower-risk MDS with poor prognosis.
Methods/design
The AZA-MDS-003 study (Additional file 1) is a multi-
center, randomized, double-blind, placebo-controlled
phase 3 trial comparing efficacy and safety of CC-486 plus
best supportive care with placebo plus best supportive
care for patients with IPSS lower-risk MDS who have
thrombocytopenia as well as RBC transfusion–dependent
anemia. This is a global study currently taking place in
19 countries, with study sites in North America (United
States, Canada, and Mexico), South America (Brazil),
Europe (Belgium, Czech Republic, Finland, France,
Germany, Italy, the Netherlands, Norway, Poland,
Portugal, Spain, Sweden, and the United Kingdom),
Asia (Israel), and Australia. A complete list of partici-
pating sites can be found at ClinicalTrials.gov.
Objectives
The primary goal of the study is to evaluate RBC trans-
fusion independence with CC-486 plus best supportive
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IPSS lower-risk MDS with RBC transfusion–dependent
anemia (average transfusion requirement of ≥ 2 units/
28 days of RBCs) and thrombocytopenia (2 platelet
counts ≤ 75 × 109/L at least 21 days apart). OS with CC-
486 vs placebo will be evaluated as an important second-
ary objective. Additional secondary objectives include
platelet transfusion independence as well as duration of
and time to platelet transfusion independence; RBC trans-
fusion independence for ≥ 56 days as well as duration of
and time to RBC transfusion independence; progression
to AML and time to AML progression; hematologic re-
sponse, including erythroid response and platelet re-
sponse; clinically significant bleeding events; safety;
health-related QOL (HRQOL); and healthcare resource
utilization.Patients
Eligible patients must be aged ≥ 18 years and have a doc-
umented diagnosis of MDS according to the World
Health Organization 2008 classification. Patients must
have RBC transfusion–dependent anemia defined as an
average transfusion requirement of ≥ 2 units/28 days of
RBCs without any consecutive 28-day gaps between
transfusions for a minimum of 56 days immediately pre-
ceding randomization. Transfusion data include the
hemoglobin value for which the transfusion was admin-
istered and must have been ≤ 10.0 g/dL within 7 days
prior to transfusion administration to be counted toward
the RBC transfusion–dependent status. Patients must
also have thrombocytopenia defined as 2 platelet counts
that are ≤ 75 × 109/L at least 21 days apart. The second
confirmatory platelet count must be obtained ≤ 14 days
prior to randomization. Eastern Cooperative Oncology
Group performance status (ECOG PS) must be 0, 1, or 2.
Patients with secondary MDS (MDS as the result of chem-
ical injury or treatment with chemotherapy and/or radi-
ation for other diseases) are eligible provided they fulfill all
other criteria. Patients with hypoplastic MDS are allowed
as long as they are not eligible for treatment with immuno-
therapy based on investigator’s judgment. Prior treatment
with lenalidomide is allowed as long as the patient received
the last dose ≥ 8 weeks prior to randomization. Patients
must understand and voluntarily sign an informed consent
document before any study related assessments or proce-
dures are conducted. The investigator will obtain the in-
formed consent and a copy of the informed consent
document will be given to the patient.
Exclusion criteria include having IPSS higher-risk (Int-2–
or high-risk) MDS. Patients must not have been previously
treated with hypomethylating agents and must not have re-
ceived prior allogeneic or autologous stem cell transplant.
Patients with uncontrolled dysfunction of other organs,such as cardiac, liver, or pulmonary failure, are also
ineligible.
Study design and treatment
This study abides by Good Clinical Practice, as de-
scribed in International Conference on Harmonisation
Guideline E6 and in accordance with the general ethical
principles outlined in the Declaration of Helsinki. The
study received approval from the institutional review
boards/ethics committee of each study site prior to
commencement (Additional file 2). The investigators
will conduct all aspects of this study in accordance with
applicable national, state, and local laws of the pertinent
regulatory authorities. An estimated 386 patients will be
randomized in a 1:1 ratio by a central randomization
procedure using Interactive Response Technology (IRT).
Investigator or designated staff will be given access to the
IRT system to enroll patients. Patients will be stratified
based on average baseline RBC transfusion requirement
(≤4 units vs > 4 units RBC per 28 days), baseline platelet
transfusion status (dependent or independent), and ECOG
PS (0–1 vs 2). Patients will receive either 300 mg of CC-
486 or placebo daily for the first 21 days of each 28-day
treatment cycle (Fig. 1, Additional file 3). Patients, care-
givers, investigators, and outcomes assessors will be
blinded to treatment assignment until all randomized
patients have received ≥ 12 months of treatment, or have
discontinued from the study. Patients may also receive
best supportive care as needed, including, but not limited
to, RBC transfusions, platelet transfusions, antimicrobial
therapy, nutritional support, and granulocyte colony-
stimulating factors for those who experience neutropenic
fever/infections and for secondary prophylaxis under cer-
tain conditions described in the protocol. Best supportive
care for this study excludes the use of other antineoplastic
therapies, erythropoiesis-stimulating agents, and other
hematopoietic growth factors or active agents where the
goal is to eradicate or slow the progression of the disease
and thereby taint the ability to clearly define the efficacy
endpoints.
At the end of cycle 6, disease status assessment will be
performed and patients may continue treatment if they
show evidence of responses including achieved RBC
transfusion independence, platelet transfusion independ-
ence (for those with platelet transfusion dependence at
baseline), hematologic improvement, ≥ 50 % reduction
in average RBC transfusion requirements, or any other
clinical benefit including no evidence of progressive
disease as deemed present by the treating physician. If
patients do not meet any of these criteria, they discon-
tinue study treatment and enter the follow-up phase for
safety assessment, subsequent MDS therapies, and sur-
vival. Patients may also discontinue treatment due to lack
of efficacy, progressive disease, or unacceptable toxicity at
N = 386 Planned
IPSS Lower-Risk MDS
 - Average baseline RBC
  transfusion requirement 
 - Baseline platelet
  transfusion status
 - ECOG PS
Response:
Continue blinded
Tx until PD
No response:
Discontinue Txa
CC-486
300 mg daily × 21 days
+
Best supportive care
28-day cycles
Placebo
Daily × 21 days
+
Best supportive care
28-day cycles
1:1
Fig. 1 AZA-MDS-003 study design. ECOG PS, Eastern Cooperative Oncology Group performance status; IPSS, International Prognostic Scoring
System; MDS, myelodysplastic syndromes; PD, progressive disease; RBC, red blood cell; Tx, treatment. a Unblinding will occur after all randomized
patients have received≥ 12 months of Tx or have discontinued from the study, whichever occurs first
Garcia-Manero et al. BMC Hematology  (2016) 16:12 Page 5 of 9any time during the study. Patients will continue to be
followed until 250 deaths have occurred, after which the
study will conclude.
Efficacy assessments
The primary efficacy endpoint for this trial is the pro-
portion of patients in the overall population achieving
RBC transfusion independence with duration ≥ 84 days
(12 weeks) during treatment. Baseline RBC transfusion
dependency is established by RBC transfusions admin-
istered during the 56 days immediately preceding and
including the date of randomization. Platelet transfu-
sion independence with duration ≥ 56 days (8 weeks) is
assessed in the proportion of patients who were platelet
transfusion dependent at baseline. Baseline platelet
transfusion requirements are established by the number
of platelet transfusions administered during the 56 days
immediately preceding and including the date of
randomization. Erythroid hematologic improvement
and platelet hematologic improvement will be assessed
according to International Working Group 2006 criteria
[28]. Hematologic response, including complete remission
(CR), partial remission, marrow CR, cytogenetic response,
and stable disease, will also be assessed using International
Working Group 2006 criteria [28].
Safety assessments
Safety analyses will be performed in the safety population,
which includes all randomized patients who received ≥ 1
dose of any study treatment (CC-486 or placebo). Safety
assessments include adverse events, monitoring for pro-
gression to AML, and second primary malignancy. Adverse
events will be graded according to the Common Termin-
ology Criteria for Adverse Events, version 4.0. Progression
to AML and development of second primary malignancies
will be monitored and reported as serious adverse events
regardless of causal relationship to treatment with CC-486or placebo. It is of interest to examine whether the ex-
tended exposure to CC-486 will lead to a reduction or
delay in occurrence of second primary malignancies as well
as progression of AML. An independent Data Monitoring
Committee composed of medical oncologists/hematolo-
gists with experience in treating MDS and a statistician will
evaluate safety during the course of the study.
HRQOL assessments
The impact of CC-486 on HRQOL relative to placebo
will be evaluated using the Functional Assessment of
Cancer Therapy–Anemia (FACT-An) [29] and EuroQol
Group EQ-5D-3 L (EQ-5D) instruments [30]. The
FACT-An addresses anemia-related symptoms, including
fatigue, and has been shown to discriminate between pa-
tients based on hemoglobin level and ECOG PS [29].
The EQ-5D is a non–disease-specific instrument that
measures general health status [30].
Healthcare resource utilization
Healthcare and medical resource utilization, as well as
cost-effectiveness/cost-utility analyses, will be conducted.
These will include reasons for and days of hospitalization,
diagnostic procedures and treatment intervention not
requiring hospitalization, concomitant medications, and
resource use associated with treatment administration for
MDS. Information will be collected through specially de-
signed case report forms and/or routine study activities.
Correlative assessments
Correlative assessments will be performed to determine
the relationship between CC-486 exposure and endpoints,
including safety, efficacy, and exploratory biomarkers.
These will be assessed using population pharmacokinetic/
pharmacodynamic approaches. The data collected will
help validate a population pharmacokinetic model for
CC-486 and aid in the identification of covariates that
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responses and efficacy and safety endpoints. Biomarker as-
sessments will include DNA sequence analysis of genes
identified as impacting MDS prognosis (eg, tumor protein
p53 [TP53], enhancer of zeste homolog 2 [EZH2], ets vari-
ant 6 [ETV6], runt-related transcription factor 1 [RUNX1],
additional sex combs like transcriptional regulator 1
[ASXL1], and tet methylcytosine dioxygenase 2 [TET2])
[31–33] and genes linked to DNA methylation (eg, TET2,
DNA [cytosine-5-]-methyltransferase 3 α [DNMT3A],
isocitrate dehydrogenase 1 [IDH1], and IDH2), measure-
ment of DNA methylation levels, and immunophenotyp-
ing by flow cytometry. Bone marrow, blood, and buccal
mucosa cells will be collected from patients in both con-
trol and treatment arms at screening.
Statistical analyses
The primary efficacy analysis will be conducted in the
intent-to-treat population and will compare the rates of
RBC transfusion independence for ≥ 84 days with CC-486
vs placebo. RBC transfusion independence for ≥ 84 days
will be analyzed and reported only once after all 386
patients have completed 12 months of double-blind treat-
ment or have been discontinued from treatment. A strati-
fied Mantel-Haenszel χ2 test, stratified for average baseline
RBC transfusion requirement (≤4 units vs > 4 units of
RBCs per 28 days), baseline platelet transfusion status
(dependent or independent), country of enrollment (Japan
vs rest of world), and ECOG PS (0–1 vs 2), at a 2-sided α
level of 0.05, will be used to compare the RBC transfusion
independence rate between the 2 treatment groups. The P
value from the stratified Mantel-Haenszel χ2 test will be
the confirmatory P value for the test of the null hypothesis
that the proportion of patients achieving RBC transfusion
independence is equal between the 2 treatment groups.
Limited information is available on the target population
for estimating the response rate for the primary endpoint
of RBC transfusion independence for ≥ 84 days for the
active treatment group. Data from a study evaluating 3
alternative dosing regimens of subcutaneous azacitidine
indicated that approximately 30 % of the subset of patients
who met the criteria for the target population defined in
this study achieved RBC transfusion independence for
≥ 84 days while on treatment (unpublished data). For the
placebo group, 2 past randomized, double-blind, placebo-
controlled phase 3 trials in RBC transfusion-dependent
patients with lower-risk MDS have demonstrated rates of
RBC transfusion independence ≥ 56 days of 2.5 to 6 % and
of RBC transfusion independence ≥ 168 to 182 days of 0
to 6 % in placebo-treated patients [34, 35]. Therefore, a
total sample size of 386 patients (193 in the active treat-
ment group and 193 in the placebo group) will have ap-
proximately 99 % power to detect the difference between
a response rate of 0.30 in the active treatment group and aresponse rate of 0.05 in the placebo group, and approxi-
mately 90 % power to detect the difference between a re-
sponse rate of 0.15 in the active treatment group and a
response rate of 0.05 in the placebo group. The power cal-
culations for response rate are based on a 2-sided α of
0.05 and test statistics on the difference of proportions
using an unpooled estimate of variance.
An analysis of the OS endpoint will also be con-
ducted at the time of the analysis of the primary effi-
cacy endpoint of RBC transfusion independence. If the
required 250 deaths have occurred (eg, study comple-
tion) at the time of the final analysis for the RBC trans-
fusion independence endpoint, then this will be the
final analysis of the OS endpoint. If not, an interim
analysis of the OS endpoint will be performed and
reported when all patients have completed 12 months
of double-blind treatment or have been discontinued
from treatment.
Power and sample-size determination will be based
on a test of the equality of the OS curves between the
CC-486 and placebo treatment groups using a strati-
fied log-rank test, with the following assumptions: (1)
a median OS of 18 months in the placebo-treated
group, which takes into account possible crossover
outside of the protocol of placebo-treated patients to
active treatment during the observation period; (2) a
median OS of 25.7 months (43 % improvement) in the
CC-486–treated group, 386 patients (193 in each
group); (3) the OS distribution is exponential with a
constant failure (hazard) rate; and (4) the accrual is
uniform during the accrual period (26 months) with an
overall dropout rate of 1 % from both treatment
groups. The study will provide approximately 80 %
power to detect a constant hazard rate ratio of 0.70
using a 2-sided log-rank test with an overall signifi-
cance level of 0.05. This will be achieved when
approximately 250 deaths have occurred in both treat-
ment groups, which is expected approximately
60 months after randomization of the first patient into
the study. An O’Brien-Fleming group sequential-type
boundary with a Lam-Demets alpha spending function
will be used to preserve the overall α level of 0.05 for
the analysis of OS in the event that OS is analyzed
twice. The required (two-sided) significance levels are
estimated to be 0.019 at the interim and 0.031 at the
final analysis for OS, but the actual levels used will de-
pend on the actual number of events at the time of the
interim analysis, if conducted. The null hypothesis for
testing the OS endpoint is that the OS distributions for
the two treatment groups are equivalent. Overall survival
curves will be estimated using Kaplan-Meier methods
and will be compared using a stratified log-rank test.
At the time of the final OS analysis, a stratified Cox
proportional hazards model will be used to estimate
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Finally, with the exception of the proportion of pa-
tients progressing to AML and time to AML progres-
sion, all secondary efficacy variables remaining will be
analyzed and reported once at the time of the analysis
of RBC transfusion independence. Patients will con-
tinue to be followed for progression to AML and sur-
vival until 250 deaths have been observed, after which
the study will conclude. Kaplan-Meier methods will be
used to estimate curves for time to event secondary
variables, and counts and percentages will be used to
describe categorical secondary variables. Safety assess-
ments will be summarized using descriptive statistics.
An analysis of covariance will be employed to assess
between-group differences in HRQOL scores, and in
the proportion of patients who achieve minimal clinic-
ally important differences in HRQOL assessments. In
general, missing data will not be imputed.
Status of the trial
The first patient was enrolled in AZA-MDS-003 in May
2013, with a target enrollment of 386 patients.
Discussion
This subgroup of patients with IPSS lower-risk MDS
with both RBC transfusion–dependent anemia and
thrombocytopenia has a poor prognosis with limited
treatment options. Although classified as lower risk,
this population has a median OS approaching that of
patients with Int-2–risk disease [9, 10]. Treatment with
CC-486 is being studied to assess its efficacy in improv-
ing OS, anemia, and thrombocytopenia and alleviating
transfusion requirements.
Severe anemia leading to transfusion dependence has
been associated with increased mortality and decreased
QOL [11, 14–16]. Additionally, transfusions can lead to
iron overload, which is linked to a number of morbid-
ities and may be an adverse prognostic factor for OS
and leukemia-free survival [11, 36]. Consequently, a
treatment that improves or eliminates transfusion re-
quirements may reduce transfusion-associated morbid-
ity and mortality and improve QOL. Thus, OS and
QOL are important endpoints for patients with lower-
risk MDS who have multiple cytopenias and transfusion
dependence. In reviewing this study, the US Food and
Drug Administration strongly recommended the inclu-
sion of OS as a secondary endpoint, and this study is
statistically powered to show a significant OS difference
of approximately 8 months between CC-486 treatment
and placebo. In addition, HRQOL will be assessed as a
secondary endpoint.
RBC transfusion dependence is associated with high
healthcare resource utilization costs that may be 2 to 3times higher than those for patients who do not receive
RBC transfusions [13, 16, 37]. It is estimated that only
30 % of this difference is explained by costs directly re-
lated to transfusions [13]. Another contributing factor
is that transfusion-dependent disease may be associated
with higher comorbidity burden and greater disease se-
verity. Thus, a treatment that improves or eliminates
transfusion requirements may also substantially reduce
associated healthcare resource utilization. This study
includes an examination of medical resource utilization
and cost-effectiveness/cost-utility analyses to determine
the impact of CC-486 treatment on this endpoint.
Biomarkers such as DNA hypermethylation, somatic
gene mutations, and aberrant immunophenotype have
been linked to MDS disease pathogenesis and prognosis
[31, 33, 38–43]. DNA hypermethylation is frequently
observed in MDS and may lead to epigenetic silencing
of tumor suppressor genes [38, 39]. Because DNA
hypermethylation is blocked by azanucleosides, there is
a rationale for evaluating the impact of DNA methyla-
tion levels on response to treatment with CC-486.
Somatic gene mutations, including mutations in the
epigenetic regulatory machinery, are also common in
MDS, and point mutations have been shown to have a
large prognostic impact on MDS, including IPSS lower-
risk MDS [31, 33, 40]. Gene mutations will be analyzed
in samples from patients enrolled in this trial to evalu-
ate their prognostic value as well as their impact on
clinical benefit of CC-486 treatment. Aberrant expres-
sion of antigens has also been demonstrated to impact
prognosis of lower-risk patients with MDS [41], and a
standardized flow cytometric scoring system has been
developed to quantify aberrant immunophenotypes that
will be used in this study [41–43].
In addition to lower-risk MDS, the CC-486 phase 3
program includes an investigation of CC-486 for the
treatment of newly diagnosed AML in the maintenance
setting. To date, no prior studies have shown an OS
benefit in the maintenance setting. The QUAZAR AML
Maintenance trial (CC-486-AML-001), a randomized,
controlled phase 3 trial to evaluate CC-486 as mainten-
ance therapy for older patients (aged ≥ 55 years) with
AML who are in first CR or CR with incomplete blood
count recovery following induction chemotherapy, is
also ongoing (NCT01757535).
The AZA-MDS-003 study is a registration trial
that will provide important clinical data that may ex-
pand treatment options with improved survival and
QOL for a specific subset of poor-prognosis MDS
patients: those with lower-risk MDS with anemia
and thrombocytopenia. This study should also pro-
vide a better understanding of the genetic mutations
that may lead to progression of disease including
AML.
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